Independent consultant, CO 80470, USA.
Public Health. 2011 Jul;125(7):464-75. doi: 10.1016/j.puhe.2011.01.016. Epub 2011 Jun 30.
Worldwide, genital warts, caused by human papillomavirus (HPV) is a common, sexually transmitted disease. The overall disease management strategy for genital warts should be determined not only by the prevalence, but also by the impact of the disease on individuals and society. The purpose of this study was therefore to investigate the epidemiological, economic and quality of life (QoL) burden of genital warts.
A systematic literature review was conducted on the epidemiology, QoL and management cost of genital warts in the USA, UK and France, based on studies published between 1998 and 2008. Due to scarcity of data, all studies reporting standardized QoL assessments among patients with genital warts were utilized, regardless of country of origin. Original studies were preferred over information cited in review articles.
Data from three countries suggest that genital warts occur in 0.06-0.23% of the population each year. Despite the fact that spontaneous remissions occur frequently (up to 40%), patients often prefer immediate treatment. While treatment can be costly in absolute terms (€163-510 per treatment episode), these costs are lower compared with other sexually transmitted infections (STIs). Modest reductions in QoL have been noted, which may be mitigated through adequate patient education and support.
While genital warts are an inconvenience for many patients, the occurrence may be lower than often quoted in the literature, and the economic burden on society is less than for other prominent STIs. However, concerted efforts to establish improved data collection and surveillance systems are needed in order to accurately define the burden of genital warts on individuals and society.
在全球范围内，人乳头瘤病毒（HPV）引起的生殖器疣是一种常见的性传播疾病。生殖器疣的整体疾病管理策略不仅应取决于其流行率，还应取决于该疾病对个人和社会的影响。因此，本研究旨在调查生殖器疣的流行病学、经济和生活质量（QoL）负担。
根据 1998 年至 2008 年期间发表的研究，对美国、英国和法国的生殖器疣的流行病学、QoL 和管理成本进行了系统的文献回顾。由于数据稀缺，所有报告生殖器疣患者标准化 QoL 评估的研究均被采用，而不论其来源国。首选原始研究，而非综述文章中引用的信息。
来自三个国家的数据表明，每年生殖器疣的发病率为 0.06-0.23%。尽管经常发生自发缓解（高达 40%），但患者通常仍希望立即治疗。尽管治疗的绝对费用较高（每次治疗费用为 163-510 欧元），但与其他性传播感染（STI）相比，这些费用较低。已注意到 QoL 有适度下降，通过充分的患者教育和支持可以减轻这种下降。
虽然生殖器疣给许多患者带来不便，但发病率可能低于文献中常引用的数字，且对社会的经济负担也小于其他主要的 STI。然而，需要做出一致努力来建立改进的数据收集和监测系统，以便准确界定生殖器疣对个人和社会的负担。
